Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal

Blood

Volumn 123, Issue 11, 2014, Pages 1729-1738

  Zhao, Xinghui ^a,b   Chen, Aili ^a,c,d   Yan, Xiaomei ^a   Zhang, Yue ^a,e   He, Fuhong ^c   Hayashi, Yoshihiro ^a   Dong, Yunzhu ^b   Rao, Yalan ^a   Li, Bo ^a,c,d   Conway, Rajeana M ^a   Maiques Diaz, Alba ^f   Elf, Shannon E ^g   Huang, Nuomin ^a   Zuber, Johannes ^h   Xiao, Zhijian ^e   Tse, William ⁱ   Tenen, Daniel G ^j,k   Wang, Qianfei ^c   Chen, Wei ^b   Mulloy, James C ^a   Nimer, Stephen D ^g,l   Huang, Gang ^a,b   more..

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^c Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^d UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^e PEKING UNION MEDICAL COLLEGE   (China)

^f Centro Nacional de Investigaciones Oncológicas   (Spain)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

ⁱ WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j HARVARD STEM CELL INSTITUTE   (United States)

^k NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^l UNIVERSITY OF MIAMI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; MIXED LINEAGE LEUKEMIA PROTEIN; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL RENEWAL; CONTROLLED STUDY; DNA FLANKING REGION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MEDIATOR; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION;

ANIMALS; BLOTTING, WESTERN; BONE MARROW TRANSPLANTATION; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MICE, INBRED C57BL; MYELOID-LYMPHOID LEUKEMIA PROTEIN; ONCOGENE PROTEINS, FUSION; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSLOCATION, GENETIC;

EID: 84897486848     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-03-489575     Document Type: Article

References (50)

1. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84(2):321-330. (Pubitemid 26042836)
2. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87(4):697-708. (Pubitemid 26386943)
3. Ichikawa M, Asai T, Chiba S, Kurokawa M, Ogawa S. Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle. 2004;3(6):722-724. (Pubitemid 40187898)
4. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008;99:33-76. (Pubitemid 350148068)
5. Tang YY, Shi J, Zhang L, et al. Energetic and functional contribution of residues in the core binding factor beta (CBFbeta) subunit to heterodimerization with CBFalpha. J Biol Chem. 2000;275(50):39579-39588. (Pubitemid 32058984)
6. Zhang L, Li Z, Yan J, et al. Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit. J Biol Chem. 2003;278(35):33097-33104. (Pubitemid 37055756)
7. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23(24):4284-4296. (Pubitemid 38765137)
8. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20(4):723-733. (Pubitemid 32167637)
9. Shang Y, Zhao X, Xu X, et al. CHIP functions an E3 ubiquitin ligase of Runx1. Biochem Biophys Res Commun. 2009;386(1):242-246.
10. Imai Y, Kurokawa M, Yamaguchi Y, et al. The corepressor mSin3A regulates phosphorylation-induced activation, intranuclear location, and stability of AML1. Mol Cell Biol. 2004;24(3):1033-1043. (Pubitemid 38112168)
11. Bae SC, Lee YH. Phosphorylation, acetylation and ubiquitination: the molecular basis of RUNX regulation. Gene. 2006;366(1):58-66. (Pubitemid 43199594)
12. Bernardin-Fried F, Kummalue T, Leijen S, Collector MI, Ravid K, Friedman AD. AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem. 2004;279(15):15678-15687. (Pubitemid 38618970)
13. Ziemin-van der Poel S, McCabe NR, Gill HJ, et al. Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci U S A. 1991;88(23):10735-10739. (Pubitemid 21915912)
14. Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002;10(5):1119-1128. (Pubitemid 35453829)
15. Hess JL. MLL: a histone methyltransferase disrupted in leukemia. Trends Mol Med. 2004;10(10):500-507. (Pubitemid 39303623)
16. Liu H, Cheng EH, Hsieh JJ. MLL fusions: pathways to leukemia. Cancer Biol Ther. 2009;8(13):1204-1211.
17. Cosgrove MS, Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J. 2010;277(8):1832-1842.
18. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002;10(5):1107- 1117. (Pubitemid 35453828)
19. Hsieh JJ, Cheng EH, Korsmeyer SJ. Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression. Cell. 2003;115(3):293-303. (Pubitemid 37487703)
20. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278(5340):1059-1064. (Pubitemid 27517875)
21. Wilkinson AC, Ballabio E, Geng H, et al. RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep. 2013;3(1):116-127.
22. Zhang Y, Chen A, Yan XM, Huang G. Disordered epigenetic regulation in MLL-related leukemia. Int J Hematol. 2012;96(4):428-437.
23. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-833. (Pubitemid 350006257)
24. Marschalek R. Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol. 2011;152(2):141-154.
25. Broeker PL, Super HG, Thirman MJ, et al. Distribution of 11q23 breakpoints within the MLL breakpoint cluster region in de novo acute leukemia and in treatment-related acute myeloid leukemia: correlation with scaffold attachment regions and topoisomerase II consensus binding sites. Blood. 1996;87(5):1912-1922.
26. Schichman SA, Caligiuri MA, Strout MP, et al. ALL-1 tandem duplication in acute myeloid leukemia with a normal karyotype involves homologous recombination between Alu elements. Cancer Res. 1994;54(16):4277-4280. (Pubitemid 24273133)
27. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Genes Chromosomes Cancer. 2003;37(3):237-251. (Pubitemid 36667562)
28. Shih LY, Liang DC, Fu JF, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia. 2006;20(2):218-223.
29. Marschalek R. Mixed lineage leukemia: roles in human malignancies and potential therapy. FEBS J. 2010;277(8):1822-1831.
30. Meyer C, Hofmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165-2176.
31. Narayanan A, Ruyechan WT, Kristie TM. The coactivator host cell factor-1 mediates Set1 and MLL1 H3K4 trimethylation at herpesvirus immediate early promoters for initiation of infection. Proc Natl Acad Sci U S A. 2007;104(26):10835-10840. (Pubitemid 47175187)
32. Robert I, Aussems M, Keutgens A, et al. Matrix metalloproteinase-9 gene induction by a truncated oncogenic NF-kappaB2 protein involves the recruitment of MLL1 and MLL2 H3K4 histone methyltransferase complexes. Oncogene. 2009;28(13):1626-1638.
33. Huang G, Zhao X, Wang L, et al. The ability of MLL to bind RUNX1 and methylate H3K4 at PU.1 regulatory regions is impaired by MDS/AML-associated RUNX1/AML1 mutations. Blood. 2011;118(25):6544-6552.
34. Huang G, Zhang P, Hirai H, et al. PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat Genet. 2008;40(1):51-60.
35. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628.
36. Zuber J, McJunkin K, Fellmann C, et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat Biotechnol. 2011;29(1):79-83.
37. Ayton PM, Chen EH, Cleary ML. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol. 2004;24(23):10470-10478. (Pubitemid 39507883)
38. Cierpicki T, Risner LE, Grembecka J, et al. Structure of the MLL CXXC domain-DNA complex and its functional role in MLL-AF9 leukemia. Nat Struct Mol Biol. 2010;17(1):62-68.
39. Zhang Y, Yan X, Sashida G, et al. Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cells. Blood. 2012;120(5):1118-1129.
40. Nishimoto N, Arai S, Ichikawa M, et al. Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. Blood. 2011;118(9):2541-2550.
41. Goyama S, Schibler J, Cunningham L, et al. Transcription factor RUNX1 promotes survival of acute myeloid leukemia cells. J Clin Invest. 2013;123(9):3876-3888.
42. Allen MD, Grummitt CG, Hilcenko C, et al. Solution structure of the nonmethyl-CpG-binding CXXC domain of the leukaemia-associated MLL histone methyltransferase. EMBO J. 2006;25(19):4503-4512. (Pubitemid 44498124)
43. Bach C, Mueller D, Buhl S, Garcia-Cuellar MP, Slany RK. Alterations of the CxxC domain preclude oncogenic activation of mixed-lineage leukemia 2. Oncogene. 2009;28(6):815-823.
44. Muntean AG, Tan J, Sitwala K, et al. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell. 2010;17(6):609-621.
45. Muntean AG, Chen W, Jones M, Granowicz EM, Maillard I, Hess JL. MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction. Blood. 2013;122(11):1914-1922.
46. He N, Chan CK, Sobhian B, et al. Human Polymerase-Associated Factor complex (PAFc) connects the Super Elongation Complex (SEC) to RNA polymerase II on chromatin. Proc Natl Acad Sci U S A. 2011;108(36):E636-E645.
47. Tan J, Muntean AG, Hess JL. PAFc, a key player in MLL-rearranged leukemogenesis. Oncotarget. 2010;1(6):461-465.
48. Chen J, Santillan DA, Koonce M, et al. Loss of MLL PHD finger 3 is necessary for MLL-ENL-induced hematopoietic stem cell immortalization. Cancer Res. 2008;68(15):6199-6207.
49. Muntean AG, Giannola D, Udager AM, Hess JL. The PHD fingers of MLL block MLL fusion protein-mediated transformation. Blood. 2008;112(12):4690-4693.
50. Benedikt A, Baltruschat S, Scholz B, et al. The leukemogenic AF4-MLL fusion protein causes P-TEFb kinase activation and altered epigenetic signatures. Leukemia. 2011;25(1):135-144.